Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).

McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, Benelli M, Romagnoli D, Bonechi M, Boccalini G, Pestrin M, Galardi F, De Luca F, Biganzoli L, Piccart M, Gradishar WJ, Chia S, Di Leo A, Malorni L.

Eur J Cancer. 2019 Jun;114:55-66. doi: 10.1016/j.ejca.2019.04.002. Epub 2019 May 3.

PMID:
31059974
2.

Early ctDNA dynamics as a surrogate for progression free survival in advanced breast cancer in the BEECH trial.

Hrebien S, Citi V, Garcia-Murillas I, Cutts R, Fenwick K, Kozarewa I, McEwen R, Ratnayake J, Maudsley R, Carr TH, de Bruin EC, Schiavon G, Oliveira M, Turner NC.

Ann Oncol. 2019 Mar 12. pii: mdz085. doi: 10.1093/annonc/mdz085. [Epub ahead of print]

PMID:
30860573
3.

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.

Turner NC, Alarcón E, Armstrong AC, Philco M, López Chuken YA, Sablin MP, Tamura K, Gómez Villanueva A, Pérez-Fidalgo JA, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Foxley A, Lindemann JPO, Maudsley R, Moschetta M, Outhwaite E, Pass M, Rugman P, Schiavon G, Oliveira M.

Ann Oncol. 2019 May 1;30(5):774-780. doi: 10.1093/annonc/mdz086.

4.

Author Correction: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2019 Apr;21(4):534. doi: 10.1038/s41556-019-0288-3.

PMID:
30842593
5.

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial.

Paoletti C, Schiavon G, Dolce EM, Darga EP, Carr TH, Geradts J, Hoch M, Klinowska T, Lindemann J, Marshall G, Morgan S, Patel P, Rowlands V, Sathiyayogan N, Aung K, Hamilton E, Patel M, Armstrong A, Jhaveri K, Im SA, Iqbal N, Butt F, Dive C, Harrington EA, Barrett JC, Baird R, Hayes DF.

Clin Cancer Res. 2018 Dec 1;24(23):5860-5872. doi: 10.1158/1078-0432.CCR-18-1569. Epub 2018 Aug 6.

PMID:
30082476
6.

Enhancer mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer.

Patten DK, Corleone G, Győrffy B, Perone Y, Slaven N, Barozzi I, Erdős E, Saiakhova A, Goddard K, Vingiani A, Shousha S, Pongor LS, Hadjiminas DJ, Schiavon G, Barry P, Palmieri C, Coombes RC, Scacheri P, Pruneri G, Magnani L.

Nat Med. 2018 Sep;24(9):1469-1480. doi: 10.1038/s41591-018-0091-x. Epub 2018 Jul 23.

7.

The Spatiotemporal Evolution of Lymph Node Spread in Early Breast Cancer.

Barry P, Vatsiou A, Spiteri I, Nichol D, Cresswell GD, Acar A, Trahearn N, Hrebien S, Garcia-Murillas I, Chkhaidze K, Ermini L, Huntingford IS, Cottom H, Zabaglo L, Koelble K, Khalique S, Rusby JE, Muscara F, Dowsett M, Maley CC, Natrajan R, Yuan Y, Schiavon G, Turner N, Sottoriva A.

Clin Cancer Res. 2018 Oct 1;24(19):4763-4770. doi: 10.1158/1078-0432.CCR-17-3374. Epub 2018 Jun 11.

8.

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.

Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA.

Clin Cancer Res. 2018 Aug 1;24(15):3510-3518. doi: 10.1158/1078-0432.CCR-17-3102. Epub 2018 Feb 13.

PMID:
29440181
9.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

10.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):360.

11.

Accurate detection of low prevalence AKT1 E17K mutation in tissue or plasma from advanced cancer patients.

de Bruin EC, Whiteley JL, Corcoran C, Kirk PM, Fox JC, Armisen J, Lindemann JPO, Schiavon G, Ambrose HJ, Kohlmann A.

PLoS One. 2017 May 4;12(5):e0175779. doi: 10.1371/journal.pone.0175779. eCollection 2017.

12.

Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.

Schindler E, Krishnan SM, Mathijssen R, Ruggiero A, Schiavon G, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):449-457. doi: 10.1002/psp4.12195. Epub 2017 May 30.

13.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G.

Ann Oncol. 2017 Nov 1;28(11):2906. doi: 10.1093/annonc/mdw551. No abstract available.

PMID:
28327895
14.

Reproducibility of Digital PCR Assays for Circulating Tumor DNA Analysis in Advanced Breast Cancer.

Hrebien S, O'Leary B, Beaney M, Schiavon G, Fribbens C, Bhambra A, Johnson R, Garcia-Murillas I, Turner N.

PLoS One. 2016 Oct 19;11(10):e0165023. doi: 10.1371/journal.pone.0165023. eCollection 2016.

15.

Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer.

Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC.

Sci Transl Med. 2015 Nov 11;7(313):313ra182. doi: 10.1126/scitranslmed.aac7551.

16.

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, Garrido JA, Dowsett M, Reis-Filho JS, Smith IE, Turner NC.

Sci Transl Med. 2015 Aug 26;7(302):302ra133. doi: 10.1126/scitranslmed.aab0021.

PMID:
26311728
17.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

18.

Primary Systemic Treatment in the Management of Operable Breast Cancer: Best Surgical Approach for Diagnosis, Biological Evaluation, and Research.

Barry PA, Schiavon G.

J Natl Cancer Inst Monogr. 2015 May;2015(51):4-8. doi: 10.1093/jncimonographs/lgv008.

PMID:
26063876
19.

The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22. Erratum in: Nat Cell Biol. 2019 Apr;21(4):534.

20.

Status of adjuvant endocrine therapy for breast cancer.

Schiavon G, Smith IE.

Breast Cancer Res. 2014;16(2):206. Review.

21.

The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough?

Smith IE, Yeo B, Schiavon G.

Am Soc Clin Oncol Educ Book. 2014:e16-24. doi: 10.14694/EdBook_AM.2014.34.e16. Review.

22.

Letter to the editor on 'Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial'.

Barry PA, Schiavon G, MacNeill FA.

Ann Oncol. 2014 Apr;25(4):909-10. doi: 10.1093/annonc/mdu030. Epub 2014 Mar 7. No abstract available.

PMID:
24608195
23.

The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases.

Schiavon G, Ruggiero A, Bekers DJ, Barry PA, Sleijfer S, Kloth J, Krestin GP, Schöffski P, Verweij J, Mathijssen RH.

Eur J Cancer. 2014 Mar;50(5):972-80. doi: 10.1016/j.ejca.2014.01.004. Epub 2014 Jan 27.

PMID:
24480402
24.

Follow-up tests to detect recurrent disease: patient's reassurance or medical need?

Smith IE, Schiavon G.

Breast. 2013 Aug;22 Suppl 2:S156-60. doi: 10.1016/j.breast.2013.07.030. Review.

PMID:
24074779
25.

Endocrine therapy for advanced/metastatic breast cancer.

Schiavon G, Smith IE.

Hematol Oncol Clin North Am. 2013 Aug;27(4):715-36, viii. doi: 10.1016/j.hoc.2013.05.004. Epub 2013 Jun 18. Review.

PMID:
23915741
26.
27.

'All action no talk': the role of HER2/neu in adjuvant therapy choice for gastric cancer.

Santini D, Vincenzi B, Pantano F, Schiavon G, Tonini G.

Ann Oncol. 2013 Jul;24(7):1715-7. doi: 10.1093/annonc/mdt172. Epub 2013 May 12. No abstract available.

PMID:
23670095
28.

Noninvasive detection of HER2 amplification with plasma DNA digital PCR.

Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC.

Clin Cancer Res. 2013 Jun 15;19(12):3276-84. doi: 10.1158/1078-0432.CCR-12-3768. Epub 2013 May 1.

29.

Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options.

Vincenzi B, Frezza AM, Schiavon G, Santini D, Dileo P, Silletta M, Delisi D, Bertoldo F, Badalamenti G, Baldi GG, Zovato S, Berardi R, Tucci M, Silvestris F, Dei Tos AP, Tirabosco R, Whelan JS, Tonini G.

Clin Sarcoma Res. 2013 Apr 17;3(1):6. doi: 10.1186/2045-3329-3-6.

30.

HLA typing in Brazilian boys with aromatic antiepileptic drug-induced DRESS.

Gaeti WP, Obreli-Neto PR, Moliterno RA, Schiavon GB, Cuman RK.

Int J Clin Pharm. 2013 Jun;35(3):319-22. doi: 10.1007/s11096-013-9770-3. Epub 2013 Apr 11.

PMID:
23575622
31.

Evaluation of patient enrollment in oncology phase I clinical trials.

van der Biessen DA, Cranendonk MA, Schiavon G, van der Holt B, Wiemer EA, Eskens FA, Verweij J, de Jonge MJ, Mathijssen RH.

Oncologist. 2013;18(3):323-9. doi: 10.1634/theoncologist.2012-0334. Epub 2013 Feb 21.

32.

Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.

Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G.

Eur J Cancer. 2013 Apr;49(6):1501-8. doi: 10.1016/j.ejca.2012.11.014. Epub 2012 Dec 22.

PMID:
23266047
33.

A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines.

Schiavon G, Tait DM, Briggs TW, Smith IE.

Clin Breast Cancer. 2013 Feb;13(1):77-80. doi: 10.1016/j.clbc.2012.10.004. Epub 2012 Nov 29. No abstract available.

PMID:
23199805
34.

Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.

Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G.

Support Care Cancer. 2013 May;21(5):1313-9. doi: 10.1007/s00520-012-1667-5. Epub 2012 Nov 30. Erratum in: Support Care Cancer. 2013 Apr;21(4):1209. Silvestris, Nicola [added].

PMID:
23196819
35.

SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors.

Oudijk L, Gaal J, Korpershoek E, van Nederveen FH, Kelly L, Schiavon G, Verweij J, Mathijssen RH, den Bakker MA, Oldenburg RA, van Loon RL, O'Sullivan MJ, de Krijger RR, Dinjens WN.

Mod Pathol. 2013 Mar;26(3):456-63. doi: 10.1038/modpathol.2012.186. Epub 2012 Nov 23.

36.

Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.

Vincenzi B, Silletta M, Schiavon G, Frezza AM, Del Vescovo R, Zobel BB, Santini D, Dei Tos AP, Tonini G.

Expert Opin Investig Drugs. 2013 Jan;22(1):1-7. doi: 10.1517/13543784.2013.742886. Epub 2012 Nov 16.

PMID:
23157681
37.

Tumor volume as an alternative response measurement for imatinib treated GIST patients.

Schiavon G, Ruggiero A, Schöffski P, van der Holt B, Bekers DJ, Eechoute K, Vandecaveye V, Krestin GP, Verweij J, Sleijfer S, Mathijssen RH.

PLoS One. 2012;7(11):e48372. doi: 10.1371/journal.pone.0048372. Epub 2012 Nov 2. Erratum in: PLoS One. 2013;8(1). doi:10.1371/annotation/0c66099f-d115-464e-95f3-f3b9412a325a.

38.

Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study.

Santini D, Vincenzi B, Guida FM, Imperatori M, Schiavon G, Venditti O, Frezza AM, Berti P, Tonini G.

Lancet Oncol. 2012 Oct;13(10):1020-4. doi: 10.1016/S1470-2045(12)70373-X. Epub 2012 Sep 18.

PMID:
22995650
39.

A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients.

Eechoute K, Fransson MN, Reyners AK, de Jong FA, Sparreboom A, van der Graaf WT, Friberg LE, Schiavon G, Wiemer EA, Verweij J, Loos WJ, Mathijssen RH, De Giorgi U.

Clin Cancer Res. 2012 Oct 15;18(20):5780-7. doi: 10.1158/1078-0432.CCR-12-0490. Epub 2012 Jul 31.

40.

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G.

Ann Oncol. 2012 Sep;23(9):2313-8. doi: 10.1093/annonc/mdr623. Epub 2012 Mar 5. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2906.

PMID:
22396447
41.

Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study.

Catalano V, Vincenzi B, Giordani P, Graziano F, Santini D, Baldelli AM, Alessandroni P, Schiavon G, Rossi D, Casadei V, D'Emidio S, Luzi Fedeli S, Tonini G, Fiorentini G.

Gastric Cancer. 2012 Oct;15(4):419-26. doi: 10.1007/s10120-011-0134-1. Epub 2012 Jan 12.

PMID:
22237659
42.

[Treatment of gastrointestinal bleeding in neonates: a case report].

Gasparella M, Schiavon G, Grotto P, Visentin S, Perrino G.

Pediatr Med Chir. 2011 May-Jun;33(3):137-40. Italian.

PMID:
22145298
43.

Iatrogenic traumas by nasogastric tube in very premature infants: our cases and literature review.

Gasparella M, Schiavon G, Bordignon L, Buffo M, Benetton C, Zanatta C, Ferro M, Zoppellaro F, Perrino G.

Pediatr Med Chir. 2011 Mar-Apr;33(2):85-8. Review.

PMID:
22111291
44.

Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.

Cooper J, Li W, You L, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO, Long SB, Erdjument-Bromage H, Zhou P, Tempst P, Giancotti FG.

Sci Signal. 2011 Aug 23;4(188):pt6. doi: 10.1126/scisignal.2002314.

PMID:
21878678
45.

PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G.

J Cell Physiol. 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889.

PMID:
21678421
46.

Biliary excretion of imatinib and its active metabolite CGP74588 during severe hepatic dysfunction.

Schiavon G, Eechoute K, Mathijssen RH, de Bruijn P, van der Bol JM, Verweij J, Sleijfer S, Loos WJ.

J Clin Pharmacol. 2012 Jul;52(7):1115-20. doi: 10.1177/0091270011409235. Epub 2011 May 20. No abstract available.

PMID:
21602518
47.

Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.

Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, Tonini G.

PLoS One. 2011 Apr 29;6(4):e19234. doi: 10.1371/journal.pone.0019234.

48.

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.

Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G.

J Cell Physiol. 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801.

PMID:
21503888
49.

Free mobility of medical oncologists across the European Union: still a false myth.

Schiavon G, Zambelli A.

Ann Oncol. 2011 Mar;22(3):746-7. doi: 10.1093/annonc/mdq747. Epub 2011 Jan 13. No abstract available.

PMID:
21239402
50.

Drug transporters and imatinib treatment: implications for clinical practice.

Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH.

Clin Cancer Res. 2011 Feb 1;17(3):406-15. doi: 10.1158/1078-0432.CCR-10-2250. Epub 2010 Dec 16. Review.

Supplemental Content

Loading ...
Support Center